Cellectis Sa Stock Today
| CLLS Stock | USD 4.83 0.14 2.99% |
PerformanceFair
| Odds Of DistressSmall
|
Cellectis is selling for under 4.83 as of the 23rd of December 2025; that is 2.99% up since the beginning of the trading day. The stock's lowest day price was 4.72. Cellectis has about a 30 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 23rd of November 2025 and ending today, the 23rd of December 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of February 2007 | Category Healthcare | Classification Health Care |
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. The company has 72.33 M outstanding shares of which 292.4 K shares are currently shorted by private and institutional investors with about 2.53 trading days to cover. More on Cellectis SA
Moving together with Cellectis Stock
Moving against Cellectis Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Cellectis Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Andre Choulika | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCellectis can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cellectis' financial leverage. It provides some insight into what part of Cellectis' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cellectis SA (CLLS) is traded on NASDAQ Exchange in USA and employs 216 people. Cellectis is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 470.53 M. Cellectis SA conducts business under Biotechnology sector and is part of Health Care industry. The entity has 72.33 M outstanding shares of which 292.4 K shares are currently shorted by private and institutional investors with about 2.53 trading days to cover.
Cellectis SA currently holds about 153.13 M in cash with 22.1 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37.
Check Cellectis Probability Of Bankruptcy
Ownership AllocationCellectis holds a total of 72.33 Million outstanding shares. Almost 86.05 percent of Cellectis outstanding shares are held by general public with 13.95 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cellectis Ownership Details
Cellectis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Wells Fargo & Co | 2025-06-30 | 17.1 K | |
| Harbour Investments, Inc. | 2025-06-30 | 4.5 K | |
| Rhumbline Advisers | 2025-06-30 | 1.9 K | |
| Jpmorgan Chase & Co | 2025-06-30 | 1.8 K | |
| Hanson Mcclain Inc | 2025-06-30 | 500 | |
| Pom Investment Strategies, Llc | 2025-06-30 | 495 | |
| Principal Securities Inc | 2025-06-30 | 179 | |
| Advisor Group Holdings, Inc. | 2025-06-30 | 100.0 | |
| Bank Of America Corp | 2025-06-30 | 77.0 | |
| Long Focus Capital Management, Llc | 2025-06-30 | 4.7 M | |
| B Group, Inc | 2025-06-30 | 3.3 M |
Cellectis SA Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Cellectis market risk premium is the additional return an investor will receive from holding Cellectis long position in a well-diversified portfolio.
| Mean Deviation | 4.8 | |||
| Semi Deviation | 5.28 | |||
| Standard Deviation | 6.36 | |||
| Variance | 40.45 |
Cellectis Stock Against Markets
Cellectis Corporate Management
| Dr MBA | Chief Officer | Profile | |
| Steven Doares | North Raleigh | Profile | |
| Valerie Cros | Principal Officer | Profile | |
| Philippe Duchateau | Chief Scientific Officer | Profile | |
| Pascalyne Wilson | Director Communications | Profile | |
| MBA MD | Chief Officer | Profile | |
| Arthur Stril | Interim Officer | Profile |
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.